WuXi AppTec Co., Ltd. (WUXIF)
OTCMKTS
· Delayed Price · Currency is USD
6.16
-1.65 (-21.13%)
Mar 28, 2025, 4:00 PM EST
WuXi AppTec Revenue
In the year 2024, WuXi AppTec had annual revenue of 37.92B CNY, down -1.97%.
Revenue
37.92B CNY
Revenue Growth
-1.97%
P/S Ratio
n/a
Revenue / Employee
962.04K CNY
Employees
39,414
Market Cap
26.64B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.92B | -760.22M | -1.97% |
| Dec 31, 2023 | 38.68B | -676.78M | -1.72% |
| Dec 31, 2022 | 39.35B | 16.45B | 71.84% |
| Dec 31, 2021 | 22.90B | 6.37B | 38.50% |
| Dec 31, 2020 | 16.54B | 3.66B | 28.46% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| SS Innovations International | 16.04M |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| American Oncology Network | 1.76B |
WuXi AppTec News
- 14 days ago - WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs - PRNewsWire
- 2 months ago - WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI) - PRNewsWire
- 3 months ago - WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year - PRNewsWire
- 4 months ago - WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating - PRNewsWire
- 5 months ago - WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year - PRNewsWire
- 5 months ago - Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY - PRNewsWire
- 6 months ago - WuXi AppTec to raise $500 mln in convertible bond sale as US restrictions loom - Reuters
- 7 months ago - US bill to restrict business with China's WuXi AppTec, BGI passes House - Reuters